At the American Society of Nephrology’s Kidney Week 2017 congress in New Orleans, results from several studies looking at the prevalence and impact of hyperkalemia were presented, alongside data for new therapies which may allow greater use of renin-angiotensin aldosterone system inhibition (RAASi) in patients with CKD and cardiac disease….
The American Society of Nephrology (ASN) Kidney Week 2017 was held in New Orleans in early November 2017. Presentations related to iron deficiency and anaemia provided updates on both benefits and risks with current available therapies. Presenters also discussed treatments under development, particularly those that focus on activating the Hypoxia-Inducible…
This week New Orleans will host the ASN Kidney Week Congress. In preparation for this year’s meeting, the COMPACT RENAL team has summarised key sessions and posters relating to iron deficiency and anaemia. Note that hyperlinks to symposia will take you to the ASN Kidney Week website, where you will…
The American Society of Nephrology – Kidney Week 2017 (ASN 2017) congress takes place October 31st to November 5th 2017 in New Orleans. In this article, the COMPACT RENAL team has highlighted key sessions and posters relating to hyperkalemia. Note that hyperlinks to symposia will take you to the ASN…
The ASN 2017 Kidney Week Congress starts this week in New Orleans. In this article, the COMPACT RENAL team has highlighted key sessions and posters relating to CKD-MBD. Note that hyperlinks to symposia will take you to the ASN Kidney Week website, where you will have the option to add…
Balancing phosphate levels and protein intake in dialysis dependent CKD patients is a significant challenge.[1] Impaired renal phosphate excretion and high protein dietary requirements frequently lead to hyperphosphatemia, which negatively impacts patients’ mineral bone health.[2] The growing elderly dialysis population is particularly challenging to manage due to its additional nutritional…
Vitamin D metabolism is central to the endocrine regulation of calcium and phosphorus homeostasis and its deficiency can result in serious morbidity including secondary hyperparathyroidism and fractures[1]. This downloadable presentation summarises the consequence of vitamin D insufficiency, discusses the vitamin D levels we should be targeting in our patients with…
The much anticipated KDIGO CKD-MBD Guidelines have recently been published (Full CKD-MBD Guidelines), along with an Executive Summary and summaries of the Evidence used in the update. The new guidelines are the result of significant effort by the KDIGO Guidelines Work Group and Evidence Review Team following the 2013 Controversies…
Patients with both chronic kidney disease and heart failure present a unique range of challenges to physicians, particularly in relation to the use of Renin Angiotensin Aldosteron System Inhibition (RAASi). Cardio-renal patients are treated with RAASi therapy at high doses[1] due to their positive effects in reducing proteinuria, hypertension and…
The KDIGO 2017 CKD-MBD Guidelines have now been officially released and are available online: 2017 KDIGO CKD-MBD Guidelines The new guidelines were developed following a Controversies Conference in 2013 that identified several areas within the 2009 Guidelines which warranted potential revision or deletion, along with a series of topics to…
Balancing the cardio-renal benefits of RAASi therapy against the risks of hyperkalaemia in CKD patients is a significant challenge. ERA-EDTA 2017 provided an update on this topic, along with the status of novel potassium (K+) binders and their role in maintaining RAASi use. This article gives an overview of the…
The CKD-MBD track at the recent ERA-EDTA 2017 Congress featured numerous sessions, focusing on a broad range of topics. In this congress review article we focus on presentations regarding phosphate binders and active vitamin D therapy. Phosphate binders: Factors influencing prescription choice The much-anticipated 2017 KDIGO guidelines update continues to…
